(1998, Neurology) and Sorenson et al
9 BPC-157 and Anti-Doping Rules BPC-157 is included in section S0 of the World Anti-Doping Agencys 2026 Prohibited List
No funds from M3 were used in the writing of this manuscript
Oral BPC-157 shows potential as a gut-targeted therapy, but its effectiveness in humans is still experimental, and outcomes may vary depending on formulation, dose, and individual digestive conditions
Additionally, the GHK-Cu complex has been shown to enhance GHKs bioavailability, particularly in terms of its antioxidant and anti-inflammatory properties (Pickart, 2008)
Documentation is provided for identity and quality verification for laboratory research use only